Latest Breaking News On - Inspirna inc - Page 1 : comparemela.com

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Merck a leading science and technology company today announced a licensing agreement with Inspirna Inc. New York NY for ompenaclid RGX202 a firstinclass oral inhibitor of the creatine transport channel SLC6A8 and SLC6A8targeting followon compounds.

New yorkUnited statesUsman oz azamEli lillyDevelopment unitEuropean society for medical oncologyInspirna incVictoria zazulinaMedical oncologyChief executive officerMedia contactMerck victoria zazulina dr usman oz azam rnadriver colorectal cancer portfolio licensing agreement inspirna rgx202 rasmutated ompenaclid slc6a8 phase ii study rasmut mcrc oncology healthcare business sector crc european society for medical esmo folfiri erbitux m9140 ceacam5 metastatic technology

Inspirna to Present at the 42nd Annual J P Morgan Healthcare Conference

Inspirna to Present at the 42nd Annual J P Morgan Healthcare Conference
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Rockefeller universityNew yorkUnited statesAl iskandariyahUsman oz azamAlexandria venture investmentsNovo holdingsLepu holdingsSilicon valley bankWuxi pharmatech healthcare fundBristol myers squibbPartnership fund for new york cityInspirna incChief executive officerHealthcare conferenceBristol myers

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUsman oz azamEli lillyInspirna incEuropean society for medical oncologyDevelopment unitVictoria zazulinaMedical oncologyChief executive officer

Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRockefeller universityAl iskandariyahAndrew hendifarProduct serviceBristol myers squibbNovo holdingsEuropean society for medical oncologyWuxi pharmatech healthcare fundAlexandria venture investmentsLepu holdingsInspirna incSinai medical centerSilicon valley bankPartnership fund for new york city

Coya Therapeutics, Inc Appoints Dieter Weinand to Its Board of Directors

Coya Therapeutics, Inc. announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand?s extensive experience, connections, and.

America phDieter weinandBoard of directors replimune group incBristol myers squibbUmoja biopharma incCoya therapeutics incEuropean federation of pharmaceutical industries associationsInternational federation of pharmaceutical manufacturersInspirna incZiel bio incCoya therapeuticsReplimune group incMnemo therapeuticsUmoja biopharmaZiel bioChief executive officer